Chronic Disease, Healthy
Conditions
Brief summary
The objective of this study is collect urine samples from healthy adult subjects and subjects with stable chronic morbidities for future testing to serve as controls and establish reference ranges in the development of new invitro diagnostic devices.
Interventions
DIAGNOSTIC_TESTUrine collection for NEPHROCLEAR CCL14 Test
Urine will be collected and banked for future analysis with the NEPHROCLEAR CCL14 Test
Sponsors
Astute Medical, Inc.
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Cohort A Inclusion Criteria: 1. Apparently healthy adults (age \> 21 years); 2. Provide written informed consent for study participation.
Exclusion criteria
1. Any known or suspected acute illness or condition - including acute infections - at the time of enrollment or within the previous 30 days; 2. Any known or suspected significant new onset or chronic morbid medical condition such as those listed in the inclusion criteria for Cohort B; 3. Trauma-related surgery within the last 6 months; 4. Any surgery, hospitalization or institutionalization (such as in a nursing home) during the previous 3 months; 5. Received any blood product transfusion within the previous 2 months; 6. Pregnant women or children; 7. Prisoners or institutionalized individuals; 8. Already provided a urine sample for this study. Cohort B Inclusion Criteria: 1. Adults (age \> 21 years); 2. One or more of the following chronic, stable morbid conditions: i. Active cancer ii. Arrhythmia (atrial fibrillation, heart block, ventricular tachycardia) iii. Chronic coagulation abnormality iv. Chronic obstructive pulmonary disease (including emphysema, chronic bronchitis, and asthma) v. Chronic pancreatitis vi. Chronic renal insufficiency vii. Congestive heart failure viii. Coronary artery disease ix. Diabetes mellitus (Type 1 or Type 2) x. Gout xi. Hyper- or hypothyroidism xii. Hyperlipidemia (includes hypercholesterolemia) xiii. Hypertension xiv. Immunocompromised xv. Inflammatory bowel disease (including Crohn's disease and ulcerative colitis) xvi. Liver cirrhosis xvii. Neuromuscular disease xviii. Peripheral vascular disease (a.k.a. peripheral artery disease) xix. Polycystic kidney disease xx. Rheumatoid arthritis xxi. Systemic Lupus Erythematosus c. Provide written informed consent for study participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reference interval as defined by Clinical and Laboratory Standards Institute guideline EP28 for urinary C-C motif chemokine 14 concentration measured with the NEPHROCLEAR CCL14 Test within each cohort | Determined for urine sample collected at baseline |
Countries
United States
Contacts
Primary ContactClinical Scientist
Outcome results
None listed